AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer
Portfolio Pulse from Vandana Singh
AstraZeneca (NASDAQ:AZN) announced positive results from the ECHO Phase 3 trial of Calquence combined with bendamustine and rituximab in treating mantle cell lymphoma (MCL). The combination showed a significant improvement in progression-free survival (PFS) and a favorable trend in overall survival (OS) compared to standard chemoimmunotherapy. The data will be presented at the European Hematology Association 2024 Hybrid Congress.
June 17, 2024 | 9:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's ECHO Phase 3 trial data shows that the Calquence combination significantly improves progression-free survival in mantle cell lymphoma patients, with a favorable trend in overall survival. This is a positive development for AstraZeneca's oncology portfolio.
The positive trial results for Calquence in treating mantle cell lymphoma are likely to boost investor confidence in AstraZeneca's oncology portfolio, potentially leading to a short-term increase in the stock price. The significant improvement in progression-free survival and the favorable trend in overall survival are highly clinically meaningful outcomes.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100